15 Best Biotech Penny Stocks to Invest in Right Now

Page 11 of 13

3. MindWalk Holdings Corp. (NASDAQ:HYFT)

Year-to-Date Return: 319.90% 

MindWalk Holdings Corp. (NASDAQ:HYFT), formerly ImmunoPrecise Antibodies, is a Bio-Native AI company combining artificial intelligence, multi-omics data, and biologics research to accelerate drug discovery. Its proprietary LensAI™ platform and HYFT technology support pharmaceutical and biotech partners in de-risking development and advancing new therapeutics.

In September 2025, the business reported record first-quarter fiscal 2026 revenue of $7.6 million, a 45% increase year-over-year, alongside expanded gross margins of 53% and reduced operating losses. The company strengthened its balance sheet with $16.1 million in net proceeds from a strategic divestiture of its Netherlands operations, enabling a sharper focus on AI-driven initiatives. This period also marked the company’s rebranding to MindWalk and ticker update to HYFT, reflecting its new identity centered on AI-enabled biologics platforms.

Strategically, MindWalk Holdings Corp. (NASDAQ:HYFT) has advanced its dengue vaccine program into preclinical manufacturing and in vivo studies, showcasing the translational potential of its LensAI platform in infectious disease research .LensAI is also being validated to predict Anti-Drug-Antibody (ADA) risk, helping partners reduce late-stage biologics development failures, making HYFT one of the best penny stocks leveraging AI in biotech innovation.

CEO Dr. Jennifer Bath emphasized HYFT’s strong capital structure and operational execution as foundations for sustainable growth. The corporation’s pivot from a wet-lab services provider to a scalable SaaS-enabled biologics platform highlights its ambition to expand market share in AI-driven pharmaceutical innovation and deliver long-term value for investors.

Page 11 of 13